Cargando…
Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers
The phenotypic presentation of monogenetic diseases is determined not only by the nature of the causative mutations but also is influenced by manifold cellular, microenvironmental, and external factors. Here, heritable extracellular matrix diseases, including dystrophic epidermolysis bullosa (DEB),...
Autores principales: | Nyström, Alexander, Bruckner-Tuderman, Leena, Kiritsi, Dimitra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505774/ https://www.ncbi.nlm.nih.gov/pubmed/34650598 http://dx.doi.org/10.3389/fgene.2021.737272 |
Ejemplares similares
-
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
por: Nyström, Alexander, et al.
Publicado: (2015) -
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
por: Diociaiuti, Andrea, et al.
Publicado: (2019) -
Newer Treatment Modalities in Epidermolysis Bullosa
por: Bruckner-Tuderman, Leena
Publicado: (2019) -
Recent advances in understanding and managing epidermolysis bullosa
por: Kiritsi, Dimitra, et al.
Publicado: (2018) -
Rat Model for Dominant Dystrophic Epidermolysis Bullosa: Glycine Substitution Reduces Collagen VII Stability and Shows Gene-Dosage Effect
por: Nyström, Alexander, et al.
Publicado: (2013)